Effects of gabapentinoids in male rats discriminating fentanyl from saline
Takato Hiranita,Shawn Flynn,Amanda K. Grisham,Erin N. Murphy,Abram E. Mijares,Charles P. France
DOI: https://doi.org/10.1124/jpet.517.922690
2024-05-15
Journal of Pharmacology and Experimental Therapeutics
Abstract:ID 92269 Poster Board 517 The opioid crisis (e.g., overdose deaths) has worsened significantly during the COVID-19 pandemic, despite a decrease in the number of prescriptions for opioids. However, the number of prescriptions for and the off-label use of gabapentinoids (gabapentin and pregabalin) as alternative medications used for chronic pain is soaring with gabapentinoids increasingly detected in opioid overdose victims, raising serious concerns about the health risks of this class of drugs. The effect of gabapentinoids on mu opioid receptor (MOR)-mediated in vivo activity is not well characterized, although a study in male rats reported that gabapentinoids decrease the potency of the opioid receptor antagonist naloxone to reverse hypoventilation by the morphinan MOR agonist heroin. Male rats (n = 8) discriminating the non-morphinan MOR agonist fentanyl (0.0032 mg/kg, intraperitoneally, i.p.) from saline under a fixed-ratio 10 schedule of food reinforcement, were used to test the following hypotheses: 1) gabapentinoids do not share discriminative stimulus effects with fentanyl; 2) gabapentinoids increase the potency of fentanyl to produce discriminative stimulus effects; and 3) gabapentinoids decrease the potency of naloxone to antagonize the discriminative stimulus effect of fentanyl. Gabapentin (10-320 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) occasioned a maximum average, respectively, of 37.8% and 46.3% fentanyl-appropriate responding, and decreased rates of responding to 6.0% and 7.4% of control. Heroin (0.032-0.1 mg/kg, i.p.) occasioned 100% fentanyl-appropriate responding whereas the stimulant drugs cocaine (0.32-10 mg/kg, i.p.) and d -methamphetamine (0.1-3.2 mg/kg, i.p.) did not increase fentanyl-appropriate responding up to doses that significantly decreased rates of responding. Acute pretreatment with gabapentin (3.2-32 mg/kg, i.p.) or pregabalin (3.2-32 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 17-fold to the left. In contrast, naloxone (0.01-1.0 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 95-fold to the right. Rightward shifts by naloxone (0.1 and 1.0 mg/kg, i.p.) in the fentanyl discrimination dose-effect function were attenuated dose-dependently by gabapentin (3.2-100 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) up to 63 fold. Similar presession treatment effects of gabapentinoids were observed with heroin. These results suggest that gabapentinoids 1) produce only partial but significant fentanyl-like discriminative stimulus effects, 2) enhance the discriminative stimulus effects of the MOR agonists including the non-morphinan (phenylpiperidine) fentanyl as well as the morphinan heroin, and 3) attenuate naloxone antagonism of the discriminative stimulus effects of the MOR agonists. These results can help guide government agencies and others develop better policies for regulating gabapentinoids and treating opioid misuse and overdose. Supported by USPHS grant R01DA058018 and the Welch Foundation (Grant AQ-0039).
pharmacology & pharmacy